GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » Interest Coverage

Laekna (HKSE:02105) Interest Coverage : 0 (At Loss) (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Laekna Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Laekna's Operating Income for the six months ended in Dec. 2024 was HK$-141.50 Mil. Laekna's Interest Expense for the six months ended in Dec. 2024 was HK$-1.82 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Laekna's Interest Coverage or its related term are showing as below:


HKSE:02105's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 119.89
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Laekna Interest Coverage Historical Data

The historical data trend for Laekna's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Laekna Interest Coverage Chart

Laekna Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Interest Coverage
- - - -

Laekna Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Interest Coverage Get a 7-Day Free Trial - - - - -

Competitive Comparison of Laekna's Interest Coverage

For the Biotechnology subindustry, Laekna's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laekna's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laekna's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Laekna's Interest Coverage falls into.


;
;

Laekna Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Laekna's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Laekna's Interest Expense was HK$-3.23 Mil. Its Operating Income was HK$-308.18 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$3.49 Mil.

Laekna did not have earnings to cover the interest expense.

Laekna's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the six months ended in Dec. 2024, Laekna's Interest Expense was HK$-1.82 Mil. Its Operating Income was HK$-141.50 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$3.49 Mil.

Laekna did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Laekna  (HKSE:02105) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Laekna Interest Coverage Related Terms

Thank you for viewing the detailed overview of Laekna's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Laekna Business Description

Traded in Other Exchanges
N/A
Address
No. 3-2-467, 5 Xingbin Road (Lin Li Center), Sino-Italy Ningbo Ecological Park, Zhejiang Province, Yuyao, CHN, 201203
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
Executives
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si 2101 Beneficial owner
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Orbimed Advisors Iii Limited 2102 Investment manager
Orbimed Asia Partners Iii, L.p. 2102 Investment manager
Orbimed Asia Gp Iii, L.p. 2102 Investment manager
Futu Trustee Limited 2301 Trustee
Lu Chris Xiangyang 2501 Other
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo 2101 Beneficial owner
Laekna Wonderland Limited 2101 Beneficial owner
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Gp Healthcare Capital, Inc. 2101 Beneficial owner
Liu Zeng 2201 Interest of corporation controlled by you
Ealex Llc 2101 Beneficial owner

Laekna Headlines

No Headlines